ICER ANALYTICS

ICER Analytics™ is a new cloud-based platform comprised of two tools - the Evidence Compendium and Interactive Modeler. The platform facilitates the use of ICER's evidence reports and underlying analyses by decision-makers as they develop medical policy, plan drug development, and plan for drug costs.

ICER EVIDENCE COMPENDIUM™

The Evidence Compendium is a rapidly searchable and sortable summary of results from over 40 ICER evidence reports, featuring: clinical effectiveness ratings, value benchmarks for each drug and indication, exclusive curated videos explaining the key takeaways from each of ICER's reports, as well as voting records and key stakeholder commentary from ICER's public meetings.

✓ Enter user generated data, and compare to value benchmarks

✓ Compare results between different treatments in a therapeutic class

✓ View manufacturers' alternative benchmarks based on updated assumptions and new evidence, published from the ICER Interactive Modeler

ICER INTERACTIVE MODELER™

The Interactive Modeler contains a modifiable rendering of the actual ICER analytic model used to produce a specific evidence report. Over 30 models are currently available in the Interactive Modeler, and the platform will grow to include models from ICER's previous, ongoing, and future assessments.

✓ Analyze key aspects of individual economic models produced for ICER evidence reports

✓ Vary parameter inputs to the model based on a specific patient sub-population or unique cost structure

✓ More accurately understand the cost-effectiveness and budget impact of health care interventions specific to your patient population

ICER ANALYTICS USE CASES

Formulary Development & Adoption

- Perform scenario analyses on the cost-effectiveness of templated formulary options
- Integrate cost-effectiveness analyses into client/plan sponsor presentations as a factor to consider in formulary adoption

Pharmacy & Therapeutics Committee

- Streamline use of ICER analyses in committee prereads & deliberations
- Use the drug "snapshot" to present ICER comparativeness effectiveness ratings, cost-effectiveness results, and consistency of proposed medication management

Budget Impact Modeling

- Configure ICER backbone-based BIM to specific population segments & clients
- Apply your market specific data and incorporate plan specific drug adoption assumptions

Outcomes-Based Agreements

- Evaluate multiple alternatives when designing or considering potential outcomes-based agreements
- Find which clinical outcomes matter most, and forecast cost amounts with different assumptions of drug effectiveness over time

For more information, please contact:

Amanda Mehlman, ICER's Director of Strategic Partnerships
Maggie Houle, ICER's Strategic Partnerships Associate
Email: analytics@icer.org